Vipoglanstat not checked

Gesynta Pharma AB · GS-248

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
4 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.”In the company’s words, NCT07260669 on ClinicalTrials.gov
Tested for
Endometriosis
Main trialPhase 2
“The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).”In the company’s words, NCT07260669 on ClinicalTrials.gov
Other names
GS-248

Other drugs for Endometriosis

All 8 drugs for Endometriosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Jun 2027 A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
Phase 2Completed 15 Jun 2022 A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
Phase 1Completed 20 Dec 2019 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
Phase 1Completed 27 May 2020 A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Vipoglanstat

Following is part of Solo: you see every change to Vipoglanstat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in